

## CHT™ Ceramic Hydroxyapatite — A New Dimension in Chromatography of Biological Molecules

Pete Gagnon<sup>1</sup>, Russ Frost<sup>2</sup>, Peter Tunón<sup>2</sup>, Tetsuro Ogawa<sup>3</sup>;

<sup>1</sup>Validated Biosystems, Inc., 5800 N Kolb Road, Suite 5127, Tucson, AZ 85750 USA;

<sup>2</sup>Bio-Rad Laboratories, 2000 Alfred Nobel Drive, Hercules CA 94547 USA;

<sup>3</sup>Asahi Optical Co., Ltd., 2-36-9, Maeno-Cho, Itabashi-Ku, Tokyo 174, Japan

### Introduction

Hydroxyapatite chromatography was introduced in 1956, but despite numerous publications describing its merits as a unique chromatography tool, it has failed to attain the popularity of ion exchange (Tiselius et al. 1956). A number of reasons account for its neglect, most of which are artificial and the remainder obsolete. In practice, it offers a unique assemblage of process characteristics that merit serious evaluation.

### Structure and Composition


The formula of hydroxyapatite is  $\text{Ca}_{10}(\text{PO}_4)_6(\text{OH})_2$  (Kawasaki et al. 1985). The functional groups comprise positively charged pairs of crystal calcium ions (C-sites) and clusters of six negatively charged oxygen atoms associated with triplets of crystal phosphates (P-sites). C-sites, P-sites, and hydroxyls are distributed in a fixed pattern on the crystal surface (Kawasaki 1978a, b, Kawasaki et al. 1985).

Hydroxyapatite made by the Tiselius method or adjustments thereto often have excess phosphate in the structure (Tiselius et al. 1956, Atkinson et al. 1973, Bernardi 1971b, Spencer 1978, Spencer and Grynpas 1978). This leads to the formation of unstable rectangular plate-shaped crystals with poor flow, pressure, and stability characteristics. Recently developed synthesis methods yield hexagonal cross-section columnar crystals with the ideal Ca:P ratio of 1.67. They can be agglomerated to form particles, and sintered at high temperatures to fuse the particles into a stable porous "ceramic" mass. This yields media that possess flow properties, capacity, and scale-up attributes that are competitive with other popular methods (Kadoya et al. 1986, Kawasaki et al. 1986a, b, Kato et al. 1988). The available surface area and pore size are affected by the sintering process used during manufacturing, and this will affect the selectivity, capacity, and separation characteristics.

### Separation Mechanism

The hydroxyapatite:biomolecule interactions are complex. The following simplified discussion is an attempt to clarify the most significant features. Amino groups are attracted

to P-sites but repelled by C-sites. The situation is reversed for carboxyls (Figure 1) (Gorbunoff 1984a, b, Gorbunoff and Timasheff 1984, Kawasaki 1991).




**Fig. 1. Protein binding to hydroxyapatite.** A is a basic protein. B is an acidic protein. Double parentheses indicate repulsion. Dotted lines indicate ionic bonds. Triangular linkages indicate coordination bonds.

Although amine-binding to P-sites and the initial attraction of carboxyls to C-sites are electrostatic, the actual binding of carboxyls to C-sites involves formation of much stronger coordination complexes between C-sites and clusters of protein carboxyls. This has been proven experimentally by evaluating the retention of proteins on which the carboxyls have been replaced by sulfo groups (Gorbunoff 1984b). Binding is reduced dramatically even though net charge is unaltered (Gorbunoff 1984b). Further proof that carboxyl/C-site binding does not reflect a classical anion exchange interaction is found in the fact that binding capacity diminishes for acidic proteins with increasing pH (Bernardi and Kawasaki 1968, Gorbunoff 1984a, b, Ogawa and Hiraide 1996).

Phosphoryl groups on proteins and other solutes interact even more strongly with C-sites than do carboxyls (Kawasaki 1991). This is reflected in extremely strong binding by phosphoproteins (Bernardi and Cook 1960). DNA does not bind as strongly as expected for a phosphoryl-rich solute. The spacing of the phosphoryl groups along the backbone apparently prevents an ideal match with the steric distribution of C-sites (Bernardi 1971a, Bernardi et al. 1972b, Kawasaki 1991, Martinson 1973, Martinson and Wagenaar 1974). DNA binds well nonetheless and the strength of the interaction increases with its size. Endotoxins bind by the numerous phosphoryl groups on their core polysaccharide and lipid-A moieties (Homma et al. 1984).

## Applications

The initial development of a buffer system for use with ceramic hydroxyapatite is a simple and straightforward process. The sample is normally loaded in low ionic strength phosphate buffer (1–10 mM sodium or potassium phosphate) at or near neutral pH. Higher loading concentrations can be advantageous (Figure 2). Elution is normally done with a gradient of phosphate buffer (100–400 mM sodium phosphate) of the same pH, but as will be seen many different combinations are possible.



**Fig. 2. The effect of phosphate concentration on protein binding.** The upper profile was loaded with 1 mM phosphate. The binding buffer for the lower profile included 50 mM phosphate. IgG binding capacity (shown in gray) was improved by reduced substrate competition with contaminants.

Binding of basic proteins becomes stronger with reducing pH, due to increasing positive charge on the protein. As a rule of thumb, the lower the pH of the buffer the stronger the binding to the support is, and the higher the molarity of the sodium phosphate buffer required to desorb the protein will be. This reflects the dominant cation exchange component of the interaction, but the selectivity is distinct from classical cation exchange. Concurrent repulsion of amines by C-sites, and the geometric distribution of charges, impart a unique stereochemical element that sometimes endows hydroxyapatite chromatography with the ability to discriminate among closely related protein variants. Examples include fractionation of light chain idiotypes from monoclonal mixtures with common heavy chains and fractionation of bifunctional antibodies from complex parent/sibling mixtures (Brooks and Stevens 1985, Bukovsky and Kennett 1987, Josic et al. 1991, Juarez-Salinas et al. 1984, 1986, Mariani et al. 1989a, b, Stanker et al. 1985).


### Antibody Purification

Antibodies constitute the most widely purified molecule class of all. Hydroxyapatite chromatography is very suitable for antibody work and antibodies can be used to illustrate the versatility of the technique. With the proper buffer scheme most antibodies can be purified with hydroxyapatite chromatography, whether they are acidic, neutral, or basic.

Antibodies that bind predominantly as acidic proteins can be applied to the column in a sufficient concentration of sodium chloride to maintain their solubility during loading (Josic et al. 1991). Tolerance of high sodium chloride allows dissociation of


ionic complexes between antibodies and acidic contaminants like DNA, thereby increasing purification performance and product binding capacity. High sodium chloride tolerance also allows sample to be loaded with no equilibration other than pH titration.

Binding of weakly interacting basic proteins can be strengthened by inclusion of 1 mM phosphate in the buffer (Gorbunoff 1984a). The free phosphate ions pair with C-sites and suppress their ability to repel amines (Figure 3). This low concentration does not interfere with ionic binding between amines and P-sites. Basic proteins can be eluted with chloride or phosphate ions in a gradient from 50–500 mM (Gorbunoff 1984a, b, Gorbunoff and Timasheff 1984, Kawasaki 1991).




**Fig. 3. Enhanced amine-binding by blocking C-site repulsion.** A is a basic protein. B is an acidic protein. Double parentheses indicate repulsion. Dotted lines indicate ionic bonds. Triangular linkages indicate coordination bonds.

Acidic solutes will not elute in sodium chloride, even at concentrations >3.0 M (Figure 4). Elution requires displacers with stronger affinity for C-sites, such as phosphate, citrate, or fluoride ions. This has important ramifications, for example for antibodies that behave as basic proteins. It means that elution can be achieved with sodium chloride, completely avoiding the risk of contamination from the bulk of acidic sample components (Figure 5) (Kawasaki 1991, Kawasaki et al. 1986). This specifically includes the ability to elute IgG under conditions where DNA and endotoxin remain quantitatively bound.




**Fig. 4. Selective dissociation of amine binding with sodium chloride.** A is a basic protein. B is an acidic protein. Triangular linkages indicate coordination bonds. Note that coordination bonds are unaffected.

Solubility of a protein in a weak phosphate solution can be an issue, especially for antibodies. Many hydroxyapatite chromatography protocols for antibody production prescribe a 10 mM phosphate loading buffer. Virtually all IgMs and many IgGs are either partially or wholly insoluble under these conditions. This is easily remedied. Most antibodies tolerate significant concentrations of sodium chloride without loss of



**Fig. 5. The first gradient goes from 0 to 500 mM sodium chloride.** The second goes from 0 to 500 mM potassium phosphate. The base buffer (A) was 0.5 M MES, 1 mM potassium phosphate, pH 6.0. The column was equilibrated in 10 column volumes (CV) of buffer A, then 2% CV of unequilibrated sample was injected and the column was washed with 2 CV of buffer A. Elution was with 10 CV of the first linear gradient, a 2 CV wash with a reverse gradient, then 10 CV of the second gradient. IgG elution shown in gray.

binding efficiency. Inclusion of 100 mM NaCl in the loading buffer has been observed to suspend solubility problems with IgMs (Figure 6) (Hansson and Nilsson 1973, Josic et al. 1991, Porath and Ui 1964).




**Fig. 6. The effect of solubilizing sodium chloride in the sample buffer.** Sample was mouse IgM (shown in gray) in ascites. The column equilibration and sample buffer for the upper profile was 5 mM sodium phosphate, 100 mM sodium chloride, pH 6.8. IgM recovery was >90%. Buffers for the lower trace were the same except lacking sodium chloride. Recovery was ~75%.

#### Viral Clearance

Hydroxyapatite chromatography supports viral clearance of 0.6–3.5 logs (Dove et al. 1990, Grun et al. 1992). In one study it provided less average clearance than other purification methods (Grun et al. 1992). In another, it outperformed size exclusion chromatography by a factor of 15, ion exchange chromatography by a factor of 75, and precipitation by a factor >150 (Dove et al. 1990). Differential clearance abilities of the chloride and phosphate elution modes have not been characterized.

#### Endotoxin Removal

Endotoxin removal can exceed 3 logs for antibodies that elute in sodium chloride. Clearance for antibodies that require phosphate elution is variable but seldom as good as 10-fold. As shown in Figure 7, endotoxin elutes continuously from 0.0–1.0 M phosphate. As with DNA, clearance efficiency depends on the relative elution position of the antibody. Removal of phenol red is similarly antibody dependent (Bukovsky and Kennett 1987).



**Fig. 7. Endotoxin elution from hydroxyapatite.** A commercial endotoxin preparation was injected onto a column equilibrated with 50 mM MES, pH 5.6, then eluted with a linear gradient from 0.0 to 1.0 M potassium phosphate.

#### Recoveries

Mass recoveries of 90% are typical. Recoveries below 80% usually reflect inadequate method development. Frequent causes include inadequate binding conditions, inadequate column equilibration, poor antibody solubility under the loading conditions, and excessively narrow pooling.

Activity recovery per mass unit of antibody is typically quantitative but may be reduced with IgMs that are exposed to low ionic strength for prolonged periods awaiting chromatography (Josic et al. 1991).

#### Conclusions

Hydroxyapatite has not been exploited to its potential as a process chromatography tool mainly for lack of suitable media and specific application guidelines, with antibodies being a prime example. With proper maintenance and method development customized to its unique characteristics, hydroxyapatite chromatography offers process capabilities on par with the best alternatives. CHT ceramic hydroxyapatite provides all the performance characteristics needed for effective scale-up.

Hydroxyapatite supports a variety of two-step procedures for purification of *in vitro* products. Hydroxyapatite combined with size exclusion chromatography is effective for IgMs; infrequently for IgGs. Two-step combinations with hydrophobic interaction chromatography can be applied to both classes, generally supporting better purification, higher capacities, and better overall process economy. Combinations with immobilized metal affinity chromatography are worth evaluation. Combinations with ion exchange chromatography may provide adequate performance but combinations of charge-based methods are generally less effective than partnerships between dissimilar separation mechanisms.

For *in vivo* applications, hydroxyapatite may provide a useful selectivity alternative to ion exchange. Its nucleic acid clearance capabilities take on special value for antibodies that elute in chloride. Processes that combine either high-salt immobilized metal affinity or hydrophobic interaction chromatography, with chloride-hydroxyapatite chromatography, especially in that order, although not necessarily in immediate sequence, promise better DNA and endotoxin removal than any other combination.

## References

- Atkinson A et al., Large-scale preparation of chromatographic grade hydroxylapatite and its application in protein separating procedures, *J Appl Chem Biotechnol* 23, 517–523 (1973)
- Bernardi G, Chromatography of nucleic acids on hydroxylapatite columns, *Methods Enzymol* 21, 95–139 (1971a)
- Bernardi G, Chromatography of proteins on hydroxylapatite, *Methods Enzymol* 22, 325–339 (1971b)
- Bernardi G and Cook WH, Separation and characterization of the two high density lipoproteins of egg yolk,  $\beta$ - and  $\beta$ -lipovitellin, *Biochim Biophys Acta* 44, 96–105 (1960)
- Bernardi G and Kawasaki T, Chromatography of polypeptides and proteins on hydroxylapatite columns, *Biochim Biophys Acta* 160, 301–310 (1968)
- Bernardi G et al., Chromatography of polypeptides and proteins on hydroxylapatite columns: some new developments, *Biochim Biophys Acta* 278, 409–420 (1972b)
- Brooks TL and Stevens A, Preparative HPLC purification of IgG and IgM monoclonal antibodies, *Am Lab* 17, 54–64 (1985)
- Bukovsky J and Kennett RH, Simple and rapid purification of monoclonal antibodies from cell culture supernatants and ascites fluids by hydroxylapatite chromatography on analytical and preparative scales, *Hybridoma* 6, 219–228 (1987)
- Dove GB et al., Purification alternatives for IgM (human) monoclonal antibodies, p 194–209 in Ladisch MR et al. (eds) ACS Symposium Series 427, American Chemical Society, Washington, DC (1990)
- Gagnon P, Purification Tools for Monoclonal Antibodies, Validated Biosystems, Inc., Tucson, AZ (1996)
- Gorbunoff MJ, The interaction of proteins with hydroxylapatite. I. Role of protein charge and structure, *Anal Biochem* 136, 425–432 (1984a)
- Gorbunoff MJ, The interaction of proteins with hydroxylapatite. II. Role of acidic and basic groups, *Anal Biochem* 136, 433–439 (1984b)
- Gorbunoff MJ and Timasheff S, The interaction of proteins with hydroxylapatite. III. Mechanism, *Anal Biochem* 136, 440–445 (1984)
- Grun JB et al., Viral removal/inactivation by purification of biopharmaceuticals, *Biopharm* 5, 22–30 (1992)
- Hansson U-B and Nilsson E, Electroimmunoassay of human immunoglobulin M of different charges, *J Immunol Methods* 2, 221–228 (1973)
- Homma JY et al. (eds), Bacterial Endotoxin: Chemical, Biological, and Clinical Aspects, Verlag Chemie, Weinheim (1984)
- Josic D et al., Purification of monoclonal antibodies by hydroxylapatite HPLC and size exclusion HPLC, *Biol Chem* 372, 149–156 (1991)
- Juarez-Salinas H et al., Ultrapurification of monoclonal antibodies by high-performance hydroxylapatite (HPHT) chromatography, *Biotechniques* 2, 164–169 (1984)
- Juarez-Salinas H et al., Separation of IgG idiotypes by high-performance hydroxylapatite chromatography, *Methods Enzymol* 121, 615–622 (1986)
- Kadoya T et al., A new spherical hydroxylapatite for high performance liquid chromatography of proteins, *J Liquid Chromatogr* 9, 3543–3557 (1986)
- Kato Y et al., High-performance hydroxylapatite chromatography of proteins, *J Chromatogr* 398, 340–346 (1988)
- Kawasaki T, Theory of chromatography of rigid molecules on hydroxylapatite columns with small loads. IV. Estimation of the adsorption energy of nucleoside polyphosphates, *J Chromatogr* 151, 95–112 (1978a)
- Kawasaki T, Theory of chromatography on hydroxylapatite columns with small loads, *J Chromatogr* 157, 7–42 (1978b)
- Kawasaki T, Hydroxylapatite as a liquid chromatographic packing, *J Chromatogr* 544, 147–184 (1991)
- Kawasaki T et al., Hydroxylapatite high-performance liquid chromatography: column performance for proteins, *Eur J Biochem* 152, 361–371 (1985)
- Kawasaki T et al., High-performance liquid chromatography using improved spherical hydroxylapatite particles as adsorbent. Efficiency and durability of the column, *Biochem Int* 13, 969–982 (1986a)
- Kawasaki T et al., High-performance liquid chromatography using spherical aggregates of hydroxylapatite micro-crystals as adsorbent, *Eur J Biochem* 157, 291–295 (1986b)
- Kawasaki T et al., Further study of hydroxylapatite high-performance liquid chromatography using both proteins and nucleic acids, and a new technique to increase chromatographic efficiency, *Eur J Biochem* 155, 249–257 (1986)
- Mariani M et al., Purification of monoclonal antibodies for in vivo use: A two-step HPLC shows equivalent performance to immunoaffinity chromatography, *Biochromatography* 4, 149–155 (1989a)
- Mariani M et al., Is mouse IgM purification on protein A possible? *Immunol Today* 10, 115–116 (1989b)
- Martinson HG, The basis of fractionation of single-stranded nucleic acids on hydroxylapatite, *Biochemistry* 12, 2731–2736 (1973)
- Martinson HG and Wagenaar EB, Hydroxylapatite-catalyzed degradation of ribonucleic acid, *Biochemistry* 13, 1641–1645 (1974)
- Ogawa T and Hiraide T, Effect of pH on gradient elution of different proteins on two types of Macro-Prep ceramic hydroxylapatite, *Am Lab* 28, 171, J, L (1996)
- Porath J and Ui N, Chemical studies on immunoglobulins. I. A new preparative procedure for  $\beta$ -globulins employing glycine-rich solvent systems, *Biochim Biophys Acta* 90, 324–333 (1964)
- Spencer M, Hydroxylapatite for chromatography. II. Sources of variability and improved methods of preparation, *J Chromatogr* 166, 435–446 (1978)
- Spencer M and Grynpas M, Hydroxylapatite for chromatography. I. Physical and chemical properties of different preparations, *J Chromatogr* 166, 423–434 (1978)
- Stanker LH et al., One-step purification of mouse monoclonal antibodies from ascites fluid by hydroxylapatite chromatography, *J Immunol Methods* 76, 157–169 (1985)
- Tiselius A et al., Protein chromatography on calcium phosphate columns, *Arch Biochem Biophys* 65, 132–155 (1956)

## Additional Information

This work was originally presented at Recovery of Biological Products VIII, in Tucson, AZ, 1996. The material is adapted from Gagnon (1996). Figures 1 and 3–8 and portions of the text are reproduced here with the permission of the author and publisher. This book contains a hands-on approach to monoclonal antibody purification, with sufficient theory to guide and support the reader through a variety of different separation scenarios. Chapter 5 is dedicated to the use of hydroxylapatite. Along with a range of specific method development and manufacturing recommendations, it includes an extensive list of references to earlier work. More information about this book can be obtained on the Internet at [www.validated.com](http://www.validated.com)

CHT ceramic hydroxylapatite has also been known as Macro-Prep<sup>®</sup> ceramic hydroxylapatite.

Visit us on the Web at [www.bio-rad.com](http://www.bio-rad.com) and learn more about ceramic hydroxylapatite and other separation materials that we supply.

Information in this tech note was current as of the date of writing (1996) and not necessarily the date this version (Rev C, 2009) was published.



**Bio-Rad**  
Laboratories, Inc.

Life Science  
Group

Web site [www.bio-rad.com](http://www.bio-rad.com) USA 800 4BIORAD Australia 61 02 9914 2800 Austria 01 877 89 01 Belgium 09 385 55 11 Brazil 55 21 3237 9400 Canada 905 364 3435 China 86 21 6426 0808 Czech Republic 420 241 430 532 Denmark 44 52 10 00 Finland 09 804 22 00 France 01 47 95 69 65 Germany 089 318 84 0 Greece 30 210 777 4396 Hong Kong 852 2789 3300 Hungary 36 1 455 8800 India 91 124 4029300 Israel 03 963 6050 Italy 39 02 216091 Japan 03 6361 7000 Korea 82 2 3473 4460 Mexico 52 555 488 7670 The Netherlands 0318 540666 New Zealand 0508 805 500 Norway 23 38 41 30 Poland 48 22 331 99 99 Portugal 351 21 472 7700 Russia 7 495 721 14 04 Singapore 65 6415 3188 South Africa 27 861 246 723 Spain 34 91 590 5200 Sweden 08 555 12700 Switzerland 061 717 95 55 Taiwan 886 2 2578 7189 United Kingdom 020 8328 2000